Applied BioCode (Taiwan) Performance
| 6598 Stock | TWD 24.55 0.20 0.82% |
On a scale of 0 to 100, Applied BioCode holds a performance score of 7. The firm shows a Beta (market volatility) of -0.66, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Applied BioCode are expected to decrease at a much lower rate. During the bear market, Applied BioCode is likely to outperform the market. Please check Applied BioCode's jensen alpha, sortino ratio, and the relationship between the standard deviation and total risk alpha , to make a quick decision on whether Applied BioCode's price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Applied BioCode are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Applied BioCode showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 847.9 M | |
| Total Cashflows From Investing Activities | -16.4 M |
Applied |
Applied BioCode Relative Risk vs. Return Landscape
If you would invest 2,210 in Applied BioCode on November 28, 2025 and sell it today you would earn a total of 245.00 from holding Applied BioCode or generate 11.09% return on investment over 90 days. Applied BioCode is generating 0.2179% of daily returns and assumes 2.3436% volatility on return distribution over the 90 days horizon. Simply put, 21% of stocks are less volatile than Applied, and 96% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Applied BioCode Target Price Odds to finish over Current Price
The tendency of Applied Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 24.55 | 90 days | 24.55 | about 7.64 |
Based on a normal probability distribution, the odds of Applied BioCode to move above the current price in 90 days from now is about 7.64 (This Applied BioCode probability density function shows the probability of Applied Stock to fall within a particular range of prices over 90 days) .
Applied BioCode Price Density |
| Price |
Predictive Modules for Applied BioCode
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Applied BioCode. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Applied BioCode Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Applied BioCode is not an exception. The market had few large corrections towards the Applied BioCode's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Applied BioCode, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Applied BioCode within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.30 | |
β | Beta against Dow Jones | -0.66 | |
σ | Overall volatility | 1.35 | |
Ir | Information ratio | 0.06 |
Applied BioCode Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Applied BioCode for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Applied BioCode can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Applied BioCode is not yet fully synchronised with the market data | |
| The company reported the revenue of 319.96 M. Net Loss for the year was (165.2 M) with profit before overhead, payroll, taxes, and interest of 189.37 M. | |
| Applied BioCode has accumulated about 819.75 M in cash with (151.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.03. | |
| Roughly 43.0% of the company shares are owned by insiders or employees |
Applied BioCode Fundamentals Growth
Applied Stock prices reflect investors' perceptions of the future prospects and financial health of Applied BioCode, and Applied BioCode fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Applied Stock performance.
| Return On Equity | -0.19 | |||
| Return On Asset | -0.0936 | |||
| Profit Margin | (0.46) % | |||
| Operating Margin | (0.47) % | |||
| Current Valuation | 1.72 B | |||
| Shares Outstanding | 81.76 M | |||
| Price To Book | 2.95 X | |||
| Price To Sales | 6.78 X | |||
| Revenue | 319.96 M | |||
| EBITDA | (111.35 M) | |||
| Cash And Equivalents | 819.75 M | |||
| Cash Per Share | 10.03 X | |||
| Total Debt | 58.4 M | |||
| Debt To Equity | 0.05 % | |||
| Book Value Per Share | 10.71 X | |||
| Cash Flow From Operations | (151.77 M) | |||
| Earnings Per Share | (2.63) X | |||
| Total Asset | 1.02 B | |||
About Applied BioCode Performance
Evaluating Applied BioCode's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Applied BioCode has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Applied BioCode has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Applied BioCode Corporation designs, develops, manufactures, and commercializes multiplex testing products for the In-Vitro diagnostics market. The company was founded in 2016 and is based in Santa Fe Springs, California. APPLIED BIOCODE operates under Medical Devices classification in Taiwan and is traded on Taiwan Stock Exchange.Things to note about Applied BioCode performance evaluation
Checking the ongoing alerts about Applied BioCode for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Applied BioCode help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Applied BioCode is not yet fully synchronised with the market data | |
| The company reported the revenue of 319.96 M. Net Loss for the year was (165.2 M) with profit before overhead, payroll, taxes, and interest of 189.37 M. | |
| Applied BioCode has accumulated about 819.75 M in cash with (151.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.03. | |
| Roughly 43.0% of the company shares are owned by insiders or employees |
- Analyzing Applied BioCode's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Applied BioCode's stock is overvalued or undervalued compared to its peers.
- Examining Applied BioCode's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Applied BioCode's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Applied BioCode's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Applied BioCode's stock. These opinions can provide insight into Applied BioCode's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Applied Stock Analysis
When running Applied BioCode's price analysis, check to measure Applied BioCode's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Applied BioCode is operating at the current time. Most of Applied BioCode's value examination focuses on studying past and present price action to predict the probability of Applied BioCode's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Applied BioCode's price. Additionally, you may evaluate how the addition of Applied BioCode to your portfolios can decrease your overall portfolio volatility.